Review of enoxaparin and its clinical applications in venous and arterial thromboembolism

Expert Opinion on Pharmacotherapy

Volumn 3, Issue 5, 2002, Pages 575-598

  Turpie, Alexander G G ^a   Mason, Jacquelinge A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Acute coronary syndromes; Anticoagulants; Deep vein thrombosis; Enoxaparin; Low molecular weight heparin; Non ST segment elevation myocardial infarction; Pulmonary embolism; Unfractionated heparin; Unstable angina; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ARTERY THROMBOSIS; BLEEDING; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG SAFETY; DRUG SELF ADMINISTRATION; DRUG STRUCTURE; HEALTH CARE COST; HEART INFARCTION; HOSPITALIZATION; HUMAN; MORBIDITY; MORTALITY; POSTOPERATIVE COMPLICATION; POSTTHROMBOSIS SYNDROME; PREDICTION; PREGNANCY; QUALITY OF LIFE; REVIEW; ST SEGMENT ELEVATION; THROMBOEMBOLISM; THROMBOPHILIA; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VEIN THROMBOSIS;

ANTICOAGULANTS; BIOLOGICAL AVAILABILITY; DRUG EVALUATION; ECONOMICS, PHARMACEUTICAL; ENOXAPARIN; EXPERT TESTIMONY; HALF-LIFE; HUMANS; MYOCARDIAL ISCHEMIA; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0036091655     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.3.5.575     Document Type: Review

References (122)

1. Management of venous and cardiovascular thrombosis: Enoxaparin
2. Insights into the pathogenesis of acute ischemic syndromes
3. Adding heparin to aspirin reduces the incidence of myocardial infarction and death in patients with unstable angina. A meta-analysis
4. Investigators: Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non Q-wave myocardial infarction. Results of the TIMI IIIB Trial. Myocardial Ischaemia
5. New therapies for unstable angina and non Q-wave myocardial infarction: Recent clinical trials
6. Enoxaparin: A review of its clinical potential in the management of coronary artery disease
7. Enoxaparin inhibits platelet-dependent thrombin generation in vivo in patients with unstable angina and nonQ-wave myocardial infarction
8. Enoxaparin, a low molecular weight heparin, inhibits platelet-dependent prothrombinase assembly and activity by factor-Xa neutralization
9. FDA alert
10. An update on heparins at the beginning of the new millennium
11. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor
12. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes
13. Low molecular weight heparin (enoxaparin) reduced restenosis following angioplasty in the hypercholesterolemic rabbit
14. Local delivery of enoxaparin to decrease restenosis after stenting: Results of initial multicenter trial
15. Inhibition of repetitive thrombus formation in the stenosed canine coronary artery by enoxaparin but not by unfractionated heparin
16. The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg
17. Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration
18. Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dalteparin, enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism)
19. Enoxaparin. A reappraisal of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disease
20. Low molecular weight heparin compared with unfractionated heparin in prevention of postoperative thrombosis
21. Prevention of venous thromboembolism
22. The epidemiology, pathogenesis and natural history of venous thrombosis
23. Prospective 12-year follow-up study of clinical and hemodynamic sequelae after deep vein thrombosis in low-risk patients (Zurich study)
24. The clinical course of deep-vein thrombosis. Prospective long-term follow-up of 528 symptomatic patients
25. Prevention of deep vein thrombosis after elective hip surgery
26. Prevention of postoperative venous thrombosis: A randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement
27. Gestational outcome in thrombophilic women with recurrent pregnancy loss treated with enoxaparin
28. A comparative trial of a low molecular weight heparin (enoxaparin) versus standard heparin for the prophylaxis of postoperative deep vein thrombosis in general surgery
29. Enoxaparin in the prevention of deep venous thrombosis after major surgery: Multicentric study
30. Coagulation abnormalities in malignancy: A review
31. Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment
32. Prolonged prophylaxis with enoxaparin for prevention of venous thromboembolism after surgery for abdominal malignancy: The ENOXACAN II study
33. A randomized controlled trial of a low molecular weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery
34. Use of enoxaparin, a low-molecular-weight heparin and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement
35. The natural history and aetiology of deep vein thrombosis after total hip replacement
36. Elective total hip replacement: Incidence, emergency readmission rate and postoperative mortality
37. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo
38. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
39. Prophylaxis for the prevention of venous thromboembolism after total knee arthroplasty. A comparison between unfractionated and low-molecular-weight heparin
40. Enoxaparin versus unfractionated heparin for prevention of venous thromboembolic disease after knee replacement surgery
41. Prevention of venous thromboembolism after knee arthroplasty. A randomised, double-blind trial comparing enoxaparin with warfarin
42. A prospective study of venous thromboembolism after major trauma
43. A comparison of low-dose heparin with low-molecular-weight heparin as prophylaxis against venous thromboembolism after major trauma
44. Thromboembolic complications after hip fracture - Prophylaxis with low molecular weight versus unfractionated heparin
45. Fatal pulmonary embolism in hospitalised medical patients
46. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients
47. Comparison of the low molecular weight heparin enoxaparin with unfractionated heparin in the prevention of venous thromboembolic events in medical patients with severe cardiopulmonary disease
48. Comparison of the low molecular weight heparin enoxaparin with unfractionated heparin in the prevention of venous thromboembolic events in patients with heart failure NYHA III/IV (PRINCE II study)
49. Comparison of the efficacy and safety of the low-molecular-weight heparin enoxaparin with unfractionated heparin in the prevention of deep vein thrombosis in patients with acute ischemic stroke
50. Thrombosis in pregnancy: Maternal and fetal issues
51. Use of antithrombotic agents during pregnancy
52. Use of antithrombotic agents during pregnancy
53. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry
54. Prospective evaluation of bone density in pregnant women receiving the low molecular weight heparin enoxaparin sodium
55. Assessment of a LMWH (enoxaparin) safety during pregnancy: A retrospective study of 624 pregnancies
56. Enoxaparin treatment in women with mechanical heart valves during pregnancy
57. Low-molecularweight heparin for prosthetic heart valves: Treatment failure
58. Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation
59. Comparison of efficacy and safety of low-molecular-weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: A meta-analysis
60. Comparison of the efficacy and safety of low molecular weight heparins and unfractionated heparin in initial treatment of deep venous thrombosis: An updated meta-analysis
61. Treatment of deep venous thrombosis with low-molecular-weight heparins. A meta-analysis
62. Low-molecular-weight heparins in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis
63. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: A meta-analysis of randomized controlled trials
64. Vitamin K antagonists or low-molecular-weight heparin for the long-term treatment of symptomatic venous thromboembolism
65. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis
66. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease
67. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis
68. Prophylaxis of venous thromboembolism: Analysis of cost effectiveness
69. Cost of long-term complications of deep venous thrombosis of the lower extremities: An analysis of a defined patient population in Sweden
70. Pharmacoeconomic model of enoxaparin versus heparin for prevention of deep vein thrombosis after total hip replacement
71. Thromboprophylaxis with low molecular weight heparin after major orthopaedic surgery is cost effective
72. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery
73. Cost-effectiveness of enoxaparin versus low-dose warfarin in the prevention of deep-vein thrombosis after total hip replacement surgery
74. Cost effectiveness of a low-molecular-weight heparin in prolonged prophylaxis against deep vein thrombosis after total hip replacement
75. Economic evaluation of enoxaparin as postdischarge prophylaxis for deep vein thrombosis (DVT) in elective hip surgery
76. A pharmacoeconomic assessment of enoxaparin and warfarin as prophylaxis for deep vein thrombosis in patients undergoing knee replacement surgery
77. Cost-effectiveness of enoxaparin versus low-dose heparin for prophylaxis against venous thrombosis after major trauma
78. Deep venous thrombosis prophylaxis in trauma: Cost analysis
79. Economic evaluation of enoxaparin versus placebo for the prevention of venous thromboembolism in acutely ill medical patients
80. Cost for in-patient care of venous thrombosis. A trial of enoxaparin versus standard heparin
81. Economic evaluation of out-patient treatment with low molecular weight heparin for proximal vein thrombosis
82. Patient outcomes and cost analysis associated with an out-patient deep venous thrombosis treatment program
83. Tissue-factor antigen and activity in human coronary atherosclerotic plaques
84. Tissue factor modulates the thrombogenicity of human atherosclerotic plaques
85. Low-molecular-weight heparins: An intriguing new twist with profound implications
86. Thrombin activity and early outcome in unstable angina pectoris
87. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction
88. Management of acute coronary syndromes: Acute coronary syndromes without persistent ST segment elevation; recommendations of the Task Force of the European Society of Cardiology
89. ACC/AHA guidelines for the management of patients with unstable angina and nonST-segment elevation myocardial infarction: Executive summary and recommendations. A report of the American College of Cardiology/American Association task force on practice guidelines (committee on the management of patients with unstable angina)
90. Comparison of low-molecular-weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC)
91. Comparison of two treatment durations (6 days and 14 days) of a low molecular weight heparin with a 6-day treatment of unfractionated heparin in the initial management of unstable angina or nonQ wave myocardial (FRAxiparine in Ischaemic Syndrome)
92. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease
93. Enoxaparin prevents death and cardiac ischaemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial
94. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis
95. Randomized trial of low molecular weight heparin (enoxaparin) versus unfractionated heparin for unstable coronary artery disease: One-year results of the ESSENCE Study. Efficacy and Safety of Subcutaneous Coronary Events
96. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina
97. Antithrombotic combination using tirofiban and enoxaparin: The ACUTE II study
98. Are treatment effects of enoxaparin (low molecular weight heparin) more marked in those undergoing percutaneous intervention (PCI): Results of ESSENCE/TIMI 11B
99. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris
100. Usefulness of intravenous enoxaparin for percutaneous coronary intervention in stable angina pectoris
101. Low molecular weight heparin in prevention of restenosis after angioplasty
102. Low-molecular-weight heparins in coronary stenting (the ENTICES trial). ENoxaparin and TIClopidine after Elective Stenting
103. A randomized, placebo-controlled trial of enoxaparin after high-risk coronary stenting: The ATLAST trial
104. Low-molecular-weight heparin therapy in percutaneous coronary intervention: The NICE 1 and NICE 4 trials
105. Enoxaparin and abciximab adjunctive pharmacotherapy during percutaneous coronary intervention
106. The use of enoxaparin and IIb/IIIa antagonists in acute coronary syndromes, including PCI: Final results of the NICE 3 study
107. Combined use of eptifibatide and enoxaparin in patients undergoing percutaneous coronary interventions: The results of the CRUISE trial
108. The Intergrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndromes Treatment (INTERACT)
109. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: Second trial of Heparin and Aspirin Therapy (HART II)
110. Does coronary artery patency improve with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction?
111. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction
112. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial
113. Cost-effectiveness analysis of enoxaparin versus unfractionated heparin for acute coronary syndromes: A Canadian hospital perspective
114. Economic assessment of low molecular weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Results from the ESSENCE randomized trial
115. Assessing the UK cost implications of the use of low molecular weight heparin in unstable coronary artery disease
116. Economic evaluation of enoxaparin sodium versus heparin in unstable angina
117. LMW heparin safety alert
118. Low molecular weight heparin boxed warning will be added to labelling; Rhône-Poulenc Rorer Lovenox reports of hematoma could apply to other LMWHs
119. Low molecular weight heparin: Biochemistry, pharmacology, perioperative prophylaxis regimens and guidelines for regional anesthetic management
120. Enoxaparin pharmacokinetics and pharmacodynamics in renal impairment
121. Enoxaparin pharmacokinetics and pharmacodynamics in obese
122. Safety and efficacy of unfractionated heparin versus enoxaparin in obese patients and patients with severe renal impairment: Analysis from the ESSENCE and TIMI 11B studies